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Abstract
BACKGROUND: Single-nucleotide polymorphism in the stromal cell-derived factor-1 (SDF-1)/CXCL12 gene had 
been associated with an increased risk of coronary artery disease (CAD). However, several published studies have 
shown inconsistent results. 
AIM: A meta-analysis was assessed to evaluate the association between SDF-1 3’A-gene polymorphism and CAD 
in the literature.
METHODS: A systematic review was conducted in accordance with PRISMA guidelines and adhering to the 
Cochrane Handbook for Systematic Reviews. The literature search strategy was carried out on April 3, 2019, from 
PubMed, EBSCO, Google Scholar, and DOAJ during 2013–2018 period using various keywords related to SDF-1, 
CXCL12, polymorphism, and CAD. Original data from the group, case-control study, English full-text, and DNA 
polymorphism assessment using polymerase chain reaction were enrolled. Gene polymorphism in A-base nucleotide 
among patients with CAD and healthy subjects were evaluated. All data were analyzed using Review Manager 5.3 
(Cochrane, Denmark) for meta-analysis.
RESULTS: Five eligible studies extracted for data analysis (2013–2018) based on the assessment of 2-independent 
reviewers. Several studies have been excluded due to irrelevant criteria evaluated. A significant result was found 
between SDF-1 3’A gene polymorphism with the increased risk of CAD in the overall effect evaluation using a fixed-
effects model (odds ratio [OR]: 2.02; 95% confidence interval 1.54-2.65; I2: 34%; p<0.001) on the forest plot.
CONCLUSION: Our meta-analysis suggests that gene polymorphism in A-base nucleotide of SDF-1/CXCL-12 was 
associated with the susceptibility of CAD. However, a bigger-scale and well-design of case-control study should be 
conducted to clarify these conclusions.
Introduction
Coronary artery disease (CAD) is one of 
cardiovascular disease which has been well known as the 
leading cause of death in both developed and developing 
countries [1]. CAD is an atherosclerotic disease that 
occurs in the coronary artery, which is manifested by 
stable angina, unstable angina, myocardial infarction, or 
sudden cardiac death [2]. The characteristic of pathological 
changes in atherosclerosis results from the endothelial 
injury or functional disorder, which is triggered by the 
abnormal accumulation of lipoproteins in the intima, as 
well as chronic inflammation [3]. As chronic inflammation, 
the immune system also plays critical roles in the initiation 
and propagation of atherosclerosis [4]. Several studies 
have shown that the dysregulation of immune cells and 
chemokines results in the progression of atherosclerosis, 
plaque instability, and the subsequent onset of acute 
coronary syndrome (ACS, including unstable angina 
pectoris and acute myocardial infarction [MI]) [4], [5].
Atherosclerosis is manifested as foam cell 
accumulation beneath the endothelial cell as well as 
smooth muscle recruitment, which leads to thrombus 
formation [5]. Several chemokines have been known to 
promote this process; one of them is stromal cell-derived 
factor-1(SDF-1). SDF-1, also called as chemokine (C-X-C 
motif) ligand 12 (CXCL12), is one of the family members 
of CXC chemokine located on chromosome 10q11.21 
and mostly known for its pivotal role in the smooth muscle 
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progenitor cells (SPCs) accumulation [6], [7]. MAPK and 
PI3K pathway also trigger the macrophage migration, 
particularly in the foam cell formation by binding of SDF-1 
to CXCR4, a G-protein coupled receptor [8]. In addition, 
the SDF-1 expression also acts as a chemoattractant to 
recruit immune leukocyte cells, such as lymphocytes and 
monocytes, and, in turn, regulates the pro-inflammation 
cascade pathway which is responsible for plaque rupture 
and the occurrence of CAD such as MI [9].
Since lymphocytes and monocytes are 
prominent in the progression of atherosclerosis, it has 
been suggested that the disruption of SDF-1 function 
plays a critical role in the pathogenesis of CAD as well 
as could be used as a prognostic biomarker [10]. The 
disruption of SDF-1 has been proposed associated 
with the genetic variability caused by single nucleotide 
polymorphism (SNP) which leads to its overexpression in 
atheroma plaque [11]. There is strong evidence that SNP 
loci in the SDF-1 genes are associated with the risk of CAD 
due to a transition of G-to-A base (G>A) at position 801 
in the 3’untranslated region (UTR) [11], [12]. However, a 
different race between Asian and Caucasian as well as the 
time of studies differ from the previous studies [11], [13]. 
Therefore, a systematic review and meta-analysis were 
performed to determine the relationship between SDF-1/
CXCL12 3’A-gene polymorphism and risk of CAD from 5 
years of current studies.
Methods
Literature eligibility criteria
Eligibility criteria were created based on the 
PICO framework. PICO criteria used in this study as 
follows: (1) Patient: Adult people; (2) Interest: CAD; 
(3) Control: non-CAD; and (4) Outcome: The polymorphism 
of SDF-1/CXCL12 AA-genes. The articles used in this 
study included all literature that provided full-text articles 
regarding the comparison of SDF-1/CXCL12 3’A-gene 
polymorphism and non-polymorphism in CAD patients. We 
exclude review, animal, anatomic, cadaveric, qualitative, 
and economic studies. Articles made by the same author in 
the same institution were performed sample evaluation to 
prevent sample duplication. We included studies published 
in Bahasa and English. Other languages were translated 
using google translate and decided by the author whether 
they include them or not. Five-year studies (2013–2018) 
were included to provide the current results.
This review included studies with adult 
participants (age 18 years or older) of both genders who 
have suffered CAD. CAD was defined as is the narrowing 
or blockage of the coronary arteries, usually caused by 
atherosclerosis. There are different terms used regarding 
CAD in this study, such as MI and coronary heart disease 
(CHD). The reviewed interest was SDF-1 3’A-gene 
polymorphism. SDF-1 3’A-gene polymorphism is defined 
as a presence of SNP (rs1065297, rs1801157, rs266089, 
rs197452, rs2839693, and/or rs10793538) in HHEX 
gene located on chromosome 10q24 participants of all 
nationalities, ethnic, and race were included in this study.
Methods for identifying evidence
We extracted the eligibility criteria (PICO) into 
keywords using Boolean operator. In this study, we 
used keywords ((stromal cell-derived factor-1) odds 
ratio (OR) stromal cell-derived factor 1) OR SDF-1) OR 
SDF1) OR CXCL 12) OR CXCL-12) OR CXCL12) AND 
(coronary artery disease) OR CAD) OR CHD) OR CHD) 
AND (polymorphism) OR gene mutations)) in PubMed, 
EBSCO, Google Scholar, and Directory of Open Access 
Journal (DOAJ) database to find the eligible studies.
The study selection process was performed by 
two independent authors (IPYP and EM) to reduce the 
possibility of discarding relevant studies. The decision of 
another author was used when a disagreement occurred. 
Duplicate records were removed. Titles and abstracts were 
screened and irrelevant studies were removed. Studies 
that passed the first screening were further evaluated for 
the compliance of the inclusion and exclusion criteria of 
this review. Finally, the studies were further evaluated for 
their quality before included in this review.
Study selection
In the first phase, the title of the literature was 
examined and irrelevant studies such as review articles, 
non-experimental studies, as well as anonymous 
authors, were removed. In the next phase, the full-
text of potentially relevant literature was retrieved and 
examined for compliance with the eligibility criteria 
of this review; the selected literature must meet the 
inclusion and exclusion criteria such as case-control 
study, including OR, as well as full-text articles. Finally, 
the selected literature was assessed for their evidence 
before being included in the final review (Figure 1).
28 titles and abstracts identified from primary search:
Pubmed           23
EBSCO              1
Google Scholar  1
DOAJ database  3
13 articles selected for full text assessment
15 articles excluded based on
abstract screening phase
Inclusion criteria based on year of
publication, method, sample size,
diagnosis of the participant, age, and
presence of SDF-1/CXCL12 AA-gene
polymorphism
8 articles obtained according to the
inclusion criteria Insufficient details and anonymous
author were excluded
5 case control studies included
Figure 1: The PRISMA diagram of literature selection in this study
Data collection
Literature that was identified merged and 
managed for further analysis. All of the selected literature 
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was thoroughly read and apprehended to extract the 
principle of the literature. An electronic data collection form 
was used to collect data from each author. The collected 
data by each author will be merged and be managed 
with software Review Manager 5.3. The data items were 
the author’s name, year of publication, method, sample 
size, diagnosis of the participant, age, and presence 
of SDF-1/CXCL12 AA-gene polymorphism. They were 
calculated for the OR and were analyzed.
Quality study assessment
Studies that complied with inclusion and 
exclusion criteria were assessed for their quality to ensure 
the validity and reliability of the studies. This process was 
done independently by two authors using a standardize 
critical appraisal tool to minimize the possibility of bias in 
the study selection. The critical appraisal tool in this study 
was the Joanna Briggs Institute (JBI) critical appraisal 
tool based on study design. A decision of the third and 
fourth authors was used when a disagreement occurred.
The cutoff point was used to determine the quality 
of the study. The cutoff point in this review was half of the 
total score in each JBI critical appraisal checklist. The low-
quality study was defined as a score below the cutoff point 
while conversely was termed as a high-quality study.
Synthesis of results
All relevant literature regarding SDF-1/CXCL12 
3’A-gene polymorphism and risk of CAD were included 
in the narrative synthesis. The OR of outcome was 
pooled and analyzed. Meta-analyses were performed 
using software Review Manager 5.3. Fixed effect 
model was used because the included studies were 
homogenous. The narrative synthesis was conducted 
systematically to gain a different perspective based on 
the previous current studies (2013–2018).
Results
The study results yielded five studies to 
be analyzed (Table 1) which can be included in the 
study [14], [15], [16], [17], [18]. All five articles were 
observational case-control studies. We did not find 
any randomized clinical trial study comparing SDF1 
AA-gene polymorphism in CAD patients and control. All 
five articles were considered as a good quality based 
on our judgment. The article searching process was 
carried out based on the PRISMA principle (Figure 1).
According to Table 1, all of the studies are using 
polymerase chain reaction technique to determine the 
polymorphism of the SDF-1 gene. A total of 1819 cases 
and 2030 control were included from five different 
studies during the 2013–2018 period. Based on those 
studies, there were 155 SNP of AA gene among CAD 
patients, compared with 104 SNP of AA gene in non-
CAD patients. The OR analysis for risk assessment 
was ranging from 1.10 to 7.37 among studies. However, 
to evaluate the overall effect regarding those studies, 
the meta-analysis using forest-plot was conducted 
(Figure 2).
Table 1: The summary of studies in this meta-analysis for the main comparison among variables
Study author Type of study Methods Subject condition Case n Control n Outcome
Mansoori et al., 2017 Observational study, 
case-control
PCR One-hundred-twenty Iranian adult patients with 
myocardial infarction and 120 healthy individual 
MI/CAD 120 No MI/CAD 120 CAD: 7 SDF1 AA gene, No 
CAD: 1 SDF1 AA gene
Borghini et al., 2014 Observational study, 
case-control
PCR Two-hundred of myocardial infarction patients and 
230 healthy individuals
MI/CAD 200 No MI/CAD 230 CAD: 12 SDF1 AA gene, No 
CAD: 21 SDF1 AA gene
Gu et al., 2013 Observational study, 
case-control
PCR Five-hundred-ninety-two patients with CAD and 625 
healthy individuals
CAD 592 No CAD 625 CAD: 101 SDF1 AA gene, No 
CAD: 54 SDF1 AA gene
Eba et al., 2018 Observational study, 
case-control
PCR Three-hundreds-ten chromosomes of CAD patients 
and 370 chromosomes of healthy individuals
CAD 310 No CAD 370 CAD: 14 SDF1 AA gene, No 
CAD: 6 SDF1 AA gene
Zhang et al., 2017 Observational study, 
case-control
PCR Five-hundred-ninety-seven patients with diagnosis of 
CHD patients and 685 healthy individual
CAD 597 No CAD 685 CAD: 21 SDF1 AA gene, No 
CAD: 22 SDF1 AA gene
PCR: Polymerase chain reaction, CAD: Coronary artery disease, MI: Myocardial infarction, SDF1: Stromal cell-derived factor-1.
Figure 2: Forest plot regarding single-nucleotide polymorphism in stromal cell-derived factor-1/chemokine (C-X-C motif) ligand 12 gene
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The forest plot in Figure 2 showed that the fixed 
effect model analysis was used due to the p-value >0.05 
in the heterogeneity test (I2 = 34%; X2 = 6.07; p = 0.19). 
The test for overall effect was assessed based on pooled 
OR, whereas finding statistically significant about 2.02 
times higher risk for CAD compared with patients without 
SNP in SDF-1 gene (p < 0.00001; 95% confidence 
interval: 1.54–2.65) (Figure 2).
To exclude the risk of publication bias, funnel 
plot assessment was conducted (Figure 3). According 
to the funnel plot, it can be assumed that all results of 
five different studies are symmetrical and this indicates 
the results of the study having a low publication bias 
(Figure 3).
Figure  3:  Funnel  plot  assessment  among  five  different  studies 
regarding single-nucleotide polymorphism in the stromal cell-derived 
factor-1 gene
Discussion
Our meta-analysis from 5 eligible studies 
indicated a significant association between the 
3’A-gene polymorphism in SDF-1 and risk of CAD. 
However, several pieces of evidence regarding 
those associations were inconclusive based on risk 
analysis. According to results, we can assume that 
genetic polymorphism will change the level expression 
of SDF-1 in the bloodstream. Genetic phenotyping 
analysis studies recently have addressed the 
association between the variation of 10q11.21 locus 
harboring SDF-1 gene, also known as CXCL-12, and 
CAD. SDF-1 belongs to a chemoattractant family 
and responsible for SPCs and endothelial progenitor 
cells (EPCs) and implicated in atherosclerosis plaque 
formation. SDF-1 also has a role in neutrophil and 
lymphocyte recruitment to atherosclerosis lesion 
and affects plaque stabilization. The SDF-1 3’A 
polymorphism (rs1065297, rs1801157, rs266089, 
rs197452, rs2839693, and/or rs10793538) in HHEX 
gene is a newly identified SNP which involves guanine 
(G) to adenosine (A) transition at UTR of SDF-1 gene. 
This mutation regulates change in SDF-1 expression 
and been linked to CAD susceptibility [10], [19], [20]. 
In contrast to G allele, mutation at A allele is found to 
correlate with SDF-1 overexpression. The effect of high 
SDF-1 production, however, remains controversial and 
the results vary across ethnic groups. There were only 
a few studies about SDF-1 3’A polymorphism existed, 
and some demonstrated a protective role of high SDF-1 
expression in AA genotype groups on CAD risk [21]. 
Conversely, studies by Mansoori et al. and Gu et al. 
demonstrated completely different findings in which 
SDF-1 3’A polymorphism related SDF-1 upregulation 
expressed significantly higher in the CAD group than in 
the non-CAD group [15], [16]. Based on those findings, 
we conducted a meta-analysis to further elaborate and 
analyze this diversity in study findings.
We performed meta-analysis from the five 
newest different studies analyzing SDF-1 3’A gene 
polymorphism in diverse ethnic background, Iranian, 
Chinese, Indian, and Italian population. The pooled OR 
from these five case-control studies suggested that the 
presence of SDF-1 3’A gene polymorphism as a genetic 
risk factor for CAD [14], [15], [16], [17], [18]. The present 
finding was in contrast to a former meta-analysis by 
Wu et al. which elaborated association between 
rs1801157/SDF-1 gene polymorphism and CHD [19]. 
In this aforementioned study, they did not specifically 
analyze the AA phenotype, instead they did five genetic 
subgroup analysis of AA, GG, AG versus GG, AA/AG 
versus GG, and AA versus AG/GG phenotypes, and 
eventually jump into the conclusion that rs1801157/
SDF-1 gene polymorphism was not increased 
susceptibility to CHD and may serve as protective 
factor for MI. However, a meta-analysis by Wu et al. 
possessed strong heterogeneity across studies due to 
a difference in CHD subtype defines across studies and 
the number of respondents recruited [19]. This meta-
analysis showed a current study from 5 years period 
(2013 to 2018) and also resulted in low publication bias 
based on the funnel plot.
The present study exclusively focused on the 
AA phenotype polymorphism, which was yet explored in 
other studies and may serve as a good foundation to a 
more solid and reliable meta-analysis in the near future. 
Nevertheless, there were still some issues that could 
be attributed to the limitation of the current study. First, 
the lack of available studies on this related field caused 
inevitably a small sample size of only 1819 total CAD 
cases. Another limitation was related to heterogeneity in 
the case of selection due to there were only five eligible 
studies during 2013–2018. Although all studies defined 
CAD cases based on coronary angiography findings, in 
three studies patients was diagnosed with MI and later 
confirmed by the invasive study to have CAD, whereas 
in studies by Eba et al. and Zhang et al., there was 
no clear explanation about the occurrent of MI in CAD 
groups [14], [18]. At the end, all those subjects shared a 
common underlying pathogenic process, atherosclerosis, 
and the SDF-1 gene polymorphism, therefore strongly 
correlated with CAD [14], [15], [16], [18].
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SDF-1 is a chemokine that regulating neutrophil 
migration to the atherosclerosis lesion [22], [23]. 
Damås et al. yielded a result that increased in SDF-1 
level associated with anti-inflammatory and matrix-
stabilizing effects in MI [22]. This effect might be a 
result from potent chemoattractant properties of SDF-1 
in recruiting EPC through binding with CXCR4 and 
CXCR7 receptors [23]. However, a higher plasma 
SDF-1 level was associated in reduced frequency 
of CD34+ cell phenotypes, a circulating cell marker 
associated with progenitor cell activity [24]. Previous 
studies have found that SDF-1 binds to the CXCR4 
receptor found on CD34+ cells and triggers CD34+ cell 
release from the bone marrow [25]. The CD34+ cell itself 
is responsible for angiogenesis and neovascularization 
to mediate ischemic healing after CAD [26]. Based on 
those results, we can assume that SDF-1 3’A-gene 
polymorphism associated with its overexpression, 
whereas inversely reduced the CD34+ cell phenotype 
as one of the protective factors against CAD. Even 
this meta-analysis showed a statistically significant 
association between SDF-1 3’A gene polymorphism 
and risk of CAD, lack number of participants included 
during 5 years study was a study limitation compared 
with the previous studies.
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